Sarah Premji, Clinical Oncology Fellow at Mayo Clinic, posted on X:
“ASCENT-04 met TNBC evaluating use of sacituzumab +pembro vs chemo + pembro in the 1st line.
baseline 50% lung 25% liver mets
 11.2 mo vs 7.8 mo imp in mPFS
 Longer DOR 16.5 mo vs 9.2 mo and higher ORR
 no inc irAE
New potential SOC!”
More posts featuring ASCO25.